https://www.selleckchem.com/pr....oducts/thiostrepton.
1. Among gout patients receiving ULT, except those receiving probenecid (aHR = 0.8, all had significantly lower risk of hyperlipidemia than gout patients without ULT (all aHR less then 0.9. Using real-time polymerase chain reaction, we found that most of the antigout drugs decreased the expression of hepatic genes related to lipogenesis in differentiated HepaRG cells. These data indicate that these antigout drugs reduce hyperlipidemia in gout patients, partly via the reduction in expression of lipogenesis-related genes, leadi
Like
Comment
Share
